A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
NCT ID: NCT06707246
Last Updated: 2024-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2024-12-15
2027-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Which treatment is more effective in patients with moderate to severe HS?
* What medical problems do participants have when taking secukimumab versus tofacitinib? Researchers will compare secukimumab versus tofacitinib to see which treatment works better to treat moderate to severe HS.
Participants will:
* Half of participants will take secukimumab every week in the first month and every four weeks thereafter till 1 year
* Another half of participants will take tofacitinib a tablet daily for 1 year
* Visit the clinic once every 2 weeks for checkups and tests in the first month, and every 4 weeks thereafter
* Keep a diary of their symptoms and the number of times they use a rescue inhaler
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Secukinumab treatment group
Participants will take secukinumab 300mg every week in the first month and every four weeks thereafter till 1 year
Secukinumab 300 MG; Tofacitinib 11mg
Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
Tofacitinib treatment group
Participants will take tofacitinib 11mg daily for 1 year
Secukinumab 300 MG; Tofacitinib 11mg
Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Secukinumab 300 MG; Tofacitinib 11mg
Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* male and female subjects aged ≥18 years old (when signing the informed consent);
* Moderate to severe hidradenitis suppurativa: Hurley stage II or III.
* Patients voluntarily participated in the study and signed informed consent.
* male and female subjects aged ≥18 years old (when signing the informed consent);
* Moderate to severe hidradenitis suppurativa: Hurley stage II or III.
* Participants had stable disease at screening and baseline, with lesions located in ≥2 anatomical areas (≥1 at Hurley stage II/III), a total of ≥3 abscesses and inflammatory nodules (AN), and C-reactive protein levels \> 3.0 mg/L.
* Participants had to have an intolerance, contraindication, or inadequate response to ≥3 months of oral antibiotic treatment for HS or relapse after discontinuation of treatment.
* Informed consents were signed according to the spirit of the Declaration of Helsinki.
* agree to receive regular treatment, follow-up, and relevant laboratory examinations in accordance with the clinical research protocol.
Exclusion Criteria
* patients who had previously used cubitumumab or tofacitinib;
* At the time of screening, the medical history, symptoms and examination results of the subjects suggested that the patients had active tuberculosis, active hepatitis B (HBV DNA\> lower limit), hepatitis C, syphilis (TPPA+ but excluding active syphilis negative) or AIDS.
* any active malignant tumor or history of malignant tumor within 5 years, except cured skin squamous cell carcinoma or basal cell carcinoma or cervical cancer in situ;
* Severe infection or systemic infection requiring intravenous anti-infection therapy or hospitalization due to infection within 4 weeks before baseline;
* Severe, progressive or uncontrolled liver disease, defined as AST or ALT elevation \> 3 times, or total bilirubin ULN elevation \>2 times, which can be rescreened after treatment;
* Baseline drainage tube count \> 20, diagnosis of inflammatory diseases other than HS, and history of chronic or recurrent infection or malignant tumor;
* history of drug abuse, attempted suicide or mental illness;
* those who participated in other clinical trials in the past 3 months;
* pregnant, breastfeeding, or planning to become pregnant during the trial;
* other conditions that the investigators thought should not be included.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Wenzhou Medical University
OTHER
Jinhua Central Hospital
OTHER
Affiliated Hospital of Jiaxing University
OTHER
Ningbo No. 1 Hospital
OTHER
The First People's Hospital of Huzhou
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiaqi Chen
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-0358
Identifier Type: -
Identifier Source: org_study_id